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Two international Round Robin studies showed good 
comparability of 5-methyltetrahydrofolate, but poor 
comparability of folic acid measured in serum by different HPLC-
MS/MS methods
Zia Fazili, Maya R. Sternberg, Neelima Paladugula, and Christine M. Pfeiffer
Division of Laboratory Sciences, National Center for Environmental Health, Centers for Disease 
Control and Prevention, Atlanta, GA
Abstract
Background—Serum folate methods produce different results. The comparability of HPLC-
MS/MS methods is not well-documented.
Objective—We conducted an international “Round Robin” investigation to assess the 
comparability, precision, and accuracy of serum folate HPLC-MS/MS methods.
Design—The CDC laboratory, 7 laboratories with independently-developed methods (group 1), 
and 6 laboratories with an adapted CDC method (group 2) analyzed folate forms in 6 serum pools 
and 6 calibrators from CDC (duplicate analysis over 2 days) and in 2 three-level reference 
materials (duplicate analysis).
Results—All laboratories measured 5-methyltetrahydrofolate (5-methylTHF) and folic acid; 
some measured additional folate forms. Geometric mean concentrations (nmol/L) for 5-
methylTHF in the 6 serum pools were 18.3 (CDC), 13.8–28.9 (group 1), and 16.8–18.6 (group 2); 
for folic acid, 3.42 (CDC), 1.09–4.74 (group 1), and 1.74–2.90 (group 2). The median imprecision 
(CV) for 5-methylTHF was 4.1% (CDC), 4.6%–11% (group 1), and 1.7%–6.0% (group 2); for 
folic acid, 6.9% (CDC), 4.9%–20% (group 1), and 3.9%–23% (group 2). The mean (SD; range) 
recovery of 5-methylTHF spiked into serum was 98% (27%; 59%–138%) for group 1 and 98% 
(10%; 82%–111%) for group 2; for folic acid, 93% (29%; 67%–198%) for group 1 and 81% 
(16%; 64%–102%) for group 2. The mean relative bias for 5-methylTHF compared to the 
reference material certificate value was 12% (CDC), -24% to 30% (group 1), and -0.6% to 16% 
(group 2); for folic acid, 73% (CDC), -47% to 578% (group 1), and -3.3% to 67% (group 2).
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Conclusions—For 5-methylTHF, group 2 laboratories demonstrated better agreement and 
precision, less variable spiking recovery, and less bias using a reference material. Laboratory 
performance for folic acid was highly variable and needs improvement. Certified reference 
materials for serum folate forms and total folate are needed to improve method accuracy.
Keywords
MeFox; tetrahydrofolate; 5-formyltetrahydrofolate; 5,10-methenyltetrahydrofolate
INTRODUCTION
Serum folate is an important biomarker to assess short-term folate status [1]. Previous 
studies focused on serum total folate and showed poor method agreement [2-5]. Little is 
known about the comparability of chromatography-based methods that measure individual 
folate forms, yet variation in biomarker concentrations across laboratories has to be 
understood to meaningfully compare data from different laboratories. While 
chromatography-based methods require complex sample preparation, they provide a high 
degree of specificity and often also high sensitivity and precision, particularly when HPLC 
is coupled to a tandem-mass spectrometer [5]. HPLC-MS/MS methods that use stable 
isotope-labeled internal standards are considered higher-order methods that offer a high 
degree of accuracy. Over the years mass spectrometers have become smaller in foot-print, 
less expensive, more robust, and thus more available to specialized reference, research, 
clinical, and public health laboratories. However, the comparability and performance of 
HPLC-MS/MS methods for serum folate forms has not yet been assessed systematically.
Several laboratories have developed isotope-dilution HPLC-MS/MS methods to quantitate 
serum folate forms [6-20]. The methods differ in how many folate forms are measured, how 
folate is extracted from the sample, what chromatography and instrumentation is used, and 
how the assay is calibrated. The Nutritional Biomarkers Laboratory at the Centers for 
Disease Control and Prevention (CDC) has successively expanded and improved its 
originally published method [6] to include folate forms beyond the 2 main circulating forms 
of 5-methyltetrahydrofolate (5-methylTHF)7 and folic acid, to automate the solid-phase 
extraction step to an 8-probe and later 96-probe system, to reduce the required specimen 
volume from 275 to 150 μL, and to achieve separation of 2 isobaric compounds, 5-
formyltetrahydrofolate (5-formylTHF) and a pyrazino-s-triazine derivative of 4α-hydroxy-5-
methylTHF (MeFox) [7-9]. Over the years, the CDC laboratory also worked with scientists 
from several research and public health laboratories who adapted the CDC method.
To generate much needed data on HPLC-MS/MS method comparability and performance, 
the CDC laboratory conducted 2 Round Robin studies with laboratories who used 
independently-developed serum folate methods and with laboratories who adapted the CDC 
method. The main objective of these studies was to investigate how comparable, precise, and 
7Abbreviations: 5-formylTHF, 5-formyltetrahydrofolate; 5-methylTHF, 5-methyltetrahydrofolate; 5,10-methenylTHF, 5,10-
methenyltetrahydrofolate; GCV, geometric coefficient of variation; ICC, intraclass correlation coefficient; LOD, limit of detection; 
NIST, National Institute of Standards and Technology; MeFox, pyrazino-s-triazine derivative of 4α-hydroxy-5-methylTHF; RC, 
repeatability coefficient; SRM, Standard Reference Material; THF, tetrahydrofolate
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accurate serum folate results were when generated by different methods in different 
laboratories. A secondary objective was to assess differences in calibrators used across 
laboratories.
SUBJECTS AND METHODS
Participating laboratories
In 2015, CDC conducted 2 international Round Robin method comparison studies: for 
laboratories who used independently-developed HPLC-MS/MS serum folate methods (group 
1) and for laboratories who previously adapted a CDC HPLC-MS/MS method (group 2). 
CDC invited 8 laboratories per group.
Samples
CDC provided each laboratory with 6 serum pools (2 sets for analysis over 2 days), 6 folate 
calibrators (2 sets for analysis over 2 days, plus a back-up set for an unplanned repeat 
analysis), and 2 three-level reference materials (1 set for analysis on 1 day). The sample IDs 
for the serum pools were blinded and the 2 sets were boxed in a different sequence. Each 
vial contained 1 mL serum. Serum pools 5 and 6 were the same base material; serum pool 6 
was spiked with each folate calibrator to assess recovery compared to the unspiked serum 
pool (10 nmol/L of 5-methylTHF and 5 nmol/L each of folic acid, MeFox, 5-formylTHF, 
tetrahydrofolate [THF], and 5,10-methenyltetrahydrofolate [5,10-methenylTHF]). Each 
serum pool was prepared by CDC from human serum obtained from anonymous blood 
donors (Tennessee Blood Services, Memphis, TN). The CDC individual folate calibrators 
had a concentration of 100 nmol/L in 0.1% ascorbic acid (1.0 mL/vial for 5-methylTHF and 
0.5 mL/vial for other folate forms). A National Institute of Standards and Technology 
(NIST) Standard Reference Material (SRM) 1955 (3 levels; 1 mL/vial) was included 
because this reference material has certified values for 5-methylTHF and reference values 
for folic acid [21]; NIST SRM 3949 (3 levels; 1 mL/vial) is a new material under 
development. Samples were stored at -70°C when not in use and shipped to laboratories on 
dry ice. Laboratories acknowledged the receipt of the shipment and its condition.
Laboratory analysis
CDC provided each laboratory with detailed instructions on how to analyze the samples. 
Each CDC folate calibrator was diluted to 20 nmol/L for 5-methylTHF (1:5 dilution) and 5 
nmol/L for other folate forms (1:20 dilution) and analyzed as an unknown sample. A mixed 
calibrator was prepared (same concentrations) and analyzed as an unknown sample. The 
serum pools and CDC calibrators were analyzed in duplicate over a period of 2 days (4 
independent measurements), while the reference materials were analyzed in duplicate on 1 
day (2 independent measurements). CDC provided each laboratory with a customized report 
template containing their individual sample IDs and requested that laboratories report the 
measured folate concentrations in nmol/L and provide the method limit of detection (LOD), 
the method reference or a short method description, and information on calibrators and 
internal standards. All laboratories used their in-house materials and protocols (e.g., 
calibrators, QC, reagents, consumables and instrumentation). The CDC laboratory also 
analyzed all study samples according to the same instructions.
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Statistical analysis
The study was designed to compare serum folate concentrations among laboratories as well 
as the repeatability of the methods used by each laboratory. Data in tables and figures are 
presented in the following sequence: CDC laboratory, group 1 laboratories, group 2 
laboratories. We opted not to calculate all-lab-means, as these estimates are influenced by 
outliers. We calculated for each laboratory and each serum pool, calibrator (individual and 
mixed), and reference material the mean concentration, SD, and CV of the 4 measurement 
results (2 results for reference materials). We used the median CV across the 6 serum pools 
as a measure of imprecision for each laboratory. We used a 2-way random effects model 
with restricted maximum likelihood estimation to partition the total variance of each 
laboratory method into between-sample variance and analytic variance, composed of 
between-day and within-day variance. The dependent variables, 5-methylTHF, folic acid, 
and MeFox concentrations, were log transformed. The random effects in the model were 
sample (6 serum pools) and day (day 1 and day 2). The model provided estimates of the 
geometric mean, the geometric coefficient of variation (GCV) for each error component, and 
the percent variance relative to the total variance for each laboratory. We calculated the 
repeatability coefficient (RC) for each laboratory (RC = √2 * 1.96 * SDlog; SDlog was the 
within-day SD estimated from the model) and reported the anti-log of the repeatability 
coefficient, rc. On the log scale, the rc is interpreted as the 95% range for the ratio between 2 
replicates on the same day (× / ÷ eRC). We determined accuracy by assessing spiking 
recovery for each folate form spiked into serum pool 6 relative to the unspiked serum pool 5. 
Recovery was calculated as {[(measured spiked sample – measured unspiked sample)/spike] 
* 100} and zero was used for the unspiked sample if the concentration was <LOD. We used 
the mean (SD) spiking recovery as a measure of accuracy for each laboratory and folate 
form. For 5-methylTHF and folic acid, we also determined accuracy using NIST SRM 1955 
by calculating the relative bias for each measurement result compared to the certificate value 
and then calculating the mean relative bias.
RESULTS
Participating laboratories
The participating laboratories were from 8 countries and used various sample extraction and 
clean-up methods as well as different chromatography and instrumentation to measure 
serum folate forms by HPLC-MS/MS (Table 1). All laboratories used reversed-phase 
chromatography at acidic pH and electrospray ionization in positive ion mode. Seven 
laboratories in group 1 (#1–#7) and 6 in group 2 (#11–#16) reported results in addition to 
the CDC laboratory (#10). All laboratories measured the 2 main folate forms 5-methylTHF 
and folic acid, while some laboratories, including the CDC laboratory, also measured other 
folate forms. Calibration ranges and LODs varied by folate form and laboratory; generally, 
calibration ranges did not exceed 100 nmol/L and LODs were <1 nmol/L (Supplemental 
Table 1). Most laboratories used compound-specific 13C5-analogues as internal standards, 
however 2 laboratories (#3 and #4) used deuterated internal standards (Supplemental Table 
1). These 2 laboratories also measured their calibrators directly without carrying them 
through the sample extraction process (Table 1). With few exceptions, most laboratories 
assigned concentrations to their folate calibrators spectrophotometrically (Supplemental 
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Table 2). Consistent molar absorptivity coefficients were used for 5-methylTHF, folic acid 
(except laboratory #1), and 5-formylTHF, but not for THF, 5,10-methenylTHF, and MeFox 
(Supplemental Table 2).
Agreement among laboratories
Based on the individual measurement results for the 6 serum pools, we observed differences 
in repeatability by sample and laboratory and the variance increased with increasing 
concentration. Visual inspection showed that for 5-methylTHF, the repeatability was poor 
for laboratories #3 and #4 and the agreement among laboratories was generally good, 
particularly in group 2 (Supplemental Figure 1). For folic acid, the repeatability was poor for 
laboratories #3 and #4; the agreement among laboratories was poor for pools 4–6 
(Supplemental Figure 2). For MeFox, the repeatability was poor for several laboratories, but 
especially for laboratories #14 and #16; the agreement among laboratories was also poor 
(Supplemental Figure 3).
We used the mean of the 4 measurement results for each of the 6 serum pools to further 
assess agreement among laboratories and calculated the group 1 and group 2 mean (SD) for 
each serum pool. The 5-methylTHF concentration ranges were similar across the groups 
(~9–38 nmol/L) (Table 2). While the grand mean among pools was similar for group 1 and 
group 2, the average SD among pools was higher for group 1 compared to group 2 (mean 
[SD]: 21.1 [5.2] and 20.1 [0.8] nmol/L, respectively). Concentrations of 5-methylTHF were 
similar across laboratories except for laboratory #3, which measured higher and had the 
widest range of results (Figure 1, panel A). The folic acid concentration ranges were also 
similar across the groups (~1–14 nmol/L) (Table 3). As seen with 5-methylTHF, the grand 
mean among pools was similar for group 1 and group 2, but the average SD was higher for 
group 1 (3.95 [1.75] and 3.72 [0.58] nmol/L, respectively). Folic acid concentrations varied 
across laboratories and laboratory #4 measured consistently higher and had the widest range 
of results (Figure 1, panel B). The MeFox concentration ranges were also similar across the 
groups (~2.5–14 nmol/L) (Table 4). The grand mean and the average SD among pools were 
similar in both groups (7.03 [1.62] and 8.42 [1.53] nmol/L). MeFox concentrations varied 
across laboratories and laboratory #16 had the widest range of results (Figure 1, panel C).
The 3 minor folate forms (5-formylTHF, THF and 5,10-methenylTHF) measured in a spiked 
serum pool generally showed reasonable agreement among laboratories with some 
exceptions: laboratories #15 and #16 measured higher for 5-formylTHF, laboratory #4 did 
not detect any THF, and laboratory #16 measured higher for THF (Table 5).
Imprecision
The imprecision (CV) for the 6 serum pools varied by laboratory and analyte (Figure 2). The 
widest CV ranges were obtained by laboratories #4 and #5 for 5-methylTHF (panel A), 
laboratories #3, #4, #5, #11, and #14 for folic acid (panel B), and laboratories #14 and #16 
for MeFox (panel C). The median CV for 5-methylTHF was 4.1% (laboratory #10), 4.6%–
11% (group 1), and 1.7%–6.0% (group 2) (Table 2). For folic acid, the median CV was 6.9% 
(laboratory #10), 4.9%–20% (group 1), and 3.9%–23% (group 2) (Table 3). For MeFox, the 
median CV was 5.6% (laboratory #10), 3.7%–5.1% (group 1), and 4.5%–30% (group 2) 
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(Table 4). The CV for the 3 minor folate forms in a spiked serum pool was generally ≤10% 
with some exceptions: laboratories #2 and #3 for 5-formylTHF, laboratory #3 for THF, and 
laboratories #6 and #16 for 5,10-methenylTHF (Table 5). In general, the imprecision 
estimates were comparable or higher than estimates published by group 1 laboratories 
(Supplemental Table 3).
Sources of variation
We assessed the magnitude of variation between samples (serum pools) and between 
measurements (between-day and within-day) of the same sample relative to the total 
variation (Table 6). The between-sample variance explained over 90% of the total variance 
for each laboratory. This parameter is also known as the intraclass correlation coefficient 
(ICC). For 5-methylTHF, the ICC was >97% for 11 of 14 laboratories (except for 
laboratories #3, #4 [lowest ICC], and #6). The between-sample GCV was similar across 
laboratories (51.3%–65.5%) except for laboratory #5 (80%). For folic acid, the ICC was 
>97% for 10 of 14 laboratories (except for laboratories #3, #4, #11 [lowest ICC], and #14). 
The between-sample GCV was similar across laboratories (98.6%–163%) except for 
laboratories #1, #2, and #5. For MeFox, the ICC was >98% for 6 of 8 laboratories (except 
for laboratories #14 and #16 [lowest ICC]). The between-sample GCV was fairly similar 
across laboratories (47.6%–75.4%).
The between-day and within-day variances made up a small percentage of the total variance. 
For 5-methylTHF, the within-day variance generally exceeded the between-day variance. 
Only 2 laboratories (#10 and #6) had a higher between-day than within-day variance. For 8 
of 14 laboratories the between-day variance was estimated to be zero and 5 of these 8 
laboratories were from group 2. For folic acid and MeFox, the contributions of between-day 
and within-day variances to the total variance were similar, albeit the within-day variance 
generally exceeded the between-day variance (except for laboratories #4 and #11 for folic 
acid).
We observed differences in the repeatability of replicates within a day across laboratories 
and analytes. A low rc is desirable, as it demonstrates higher repeatability between pairs of 
measurements for a given analyte. Laboratories #3 and #4 had the highest rc of 
approximately 1.3 for 5-methylTHF. This value can be used to construct a 95% range for the 
ratio between 2 replicates on the same day as (1.3-1, 1.3); in other words, 95% of the ratio of 
pairs of replicates is expected to fall between 0.77 and 1.3. For folic acid, laboratories #3, 
#5, #11 and #14 (highest rc) all had an rc >1.5. For MeFox, laboratories #14 and #16 had the 
highest rc. On average, folic acid had the worst relative repeatability compared to 5-
methylTHF and MeFox, though laboratory #16 had an rc for MeFox (2.27) that was higher 
than any other reported rc.
Accuracy
The spiking recovery of 5-methylTHF varied by laboratory (Table 7), with group 1 (mean 
[SD], range: 98% [27%], 59%–138%) reporting higher variation than group 2 (98% [10%], 
82%–111%). Laboratory #10, laboratories #1 and #5 (group 1), and laboratories #13 to #16 
(group 2) achieved nearly complete spiking recovery (100% ± 10%). The spiking recovery 
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of folic acid also varied by laboratory (group 1: 93% [47%], 67%–198%; group 2: 81% 
[14%], 64%–102%), but was incomplete for most laboratories. The spiking recovery of 
MeFox was nearly complete for laboratories #7, #10, #13, and #16. Spiking recoveries for 
the 3 minor folate forms were quite different by laboratory. Some laboratories obtained 
highly unusual recoveries for 5-formylTHF (#15 and #16) and for THF (#4 and #16). 
Spiking recoveries were mostly comparable, but some were lower or higher than estimates 
published by group 1 laboratories (Supplemental Table 3).
We evaluated accuracy for 5-methylTHF and PGA using NIST SRM 1955 (Figure 3). 
Laboratory #3 had the largest positive bias and widest bias range compared to the reference 
material certificate value for both 5-methylTHF (panel A) and folic acid (panel B). The 
mean relative bias was 12% (laboratory #10), -24% to 30% (group 1), and -0.6% to 16% 
(group 2) for 5-methylTHF; and 73% (laboratory #10), -47% to 578% (group 1), and -3.3% 
to 67% (group 2) for folic acid (Table 8). While NIST SRM 1955 cannot be used to assess 
accuracy of MeFox, we observed similar concentrations among laboratories (Supplemental 
Table 4). Results for the 3 minor folate forms were nearly all <LOD and are not presented. 
Results for a NIST reference material under development (SRM 3949) also showed similar 
5-methylTHF concentrations among laboratories, but variable folic acid concentrations 
(Supplemental Table 5). Results for MeFox (levels 1–3) and for the 3 minor forms (level 3) 
were generally similar with some exceptions: laboratory #16 measured lower for MeFox, 
laboratory #4 measured lower for 5-formylTHF, and laboratories #15 and #16 measured 
higher for 5-formylTHF (Supplemental Table 6). Results for the 3 minor folate forms for 
levels 1–2 are not presented (mostly <LOD).
CDC folate calibrators
We found good agreement among laboratories for the CDC 5-methylTHF calibrator, 
measured individually (single) or in a mixture with other calibrators (mix), but much poorer 
agreement for the other folate forms (Figure 3 and Supplemental Table 7). While the mean 
concentrations for the 3 main analytes were similar for group 1 and group 2, the SD was 
higher for group 1: 5-methylTHF (target: 20 nmol/L): mean (SD), 20.5 (1.84) vs. 19.8 (0.62) 
nmol/L; folic acid: (target: 5 nmol/L): 3.83 (1.61) vs. 3.36 (0.83) nmol/L; MeFox (target: 5 
nmol/L): 4.56 (1.12) vs. 5.16 (0.24) nmol/L. For the 3 minor folate forms, the agreement 
among laboratories was lower and the SD was higher compared to the 3 major folate forms. 
Some notable abnormal results were obtained for 5-formylTHF (laboratory #15) and for 
THF (laboratories #4 and #16). For some laboratories we noticed differences between the 
single calibrator and the mixed calibrator for 5-formylTHF and 5,10-methenylTHF, which 
can be due to pH dependent folate interconversions. When we calculated non-methylfolate 
(sum of 5-formylTHF, THF, and 5,10-methenylTHF) in the mixed calibrator for the 9 
laboratories that measured these 3 folate forms, 5 laboratories (#5, #7, #10, #13, and #14) 
obtained results within 1 nmol/L of the target value of 15 nmol/L, while laboratories #4 (9.4 
nmol/L) and #6 (11.7 nmol/L) underestimated and laboratories #15 (22.4 nmol/L) and #16 
(28.3 nmol/L) overestimated the target value (Supplemental Table 7).
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DISCUSSION
The 2 current international studies for independently-developed (group 1) and adapted CDC 
methods (group 2) provide results for 13 laboratories plus the CDC laboratory and are to our 
knowledge the first investigation where comparability, precision, and accuracy for serum 
folate HPLC-MS/MS methods were systematically assessed. The laboratory comparability 
was good for 5-methylTHF, but poor for folic acid and MeFox. Given the higher 5-
methylTHF serum concentrations compared to other folate forms, it was not surprising that 
precision and accuracy were best for this compound. However, we noted differences in 
method performance among laboratories and generally better performance in group 2 than in 
group 1 laboratories.
NIST reference materials (SRM 1955 and SRM 1950) with certified 5-methylTHF 
concentrations have been available for years, which may be another reason why we obtained 
the best performance for this compound. SRM 1955 was value assigned in 2004 by 4 
independent NIST methods and the CDC method [23]. Twelve of 14 laboratories agreed 
within ±20% of the certified values for SRM 1955. Laboratories #5 (-24%) and #3 (30%) 
deviated most from certificate values. These 2 laboratories also had the highest mean 
difference from the CDC laboratory in serum pools (-23% and 59%, respectively), while 
other laboratories agreed within ±10% (Supplemental Table 8). The discrepancy for 
laboratory #5 does not appear to be calibration related, because of their close agreement with 
the target value for the 5-methylTHF calibrator (19.6 vs. 20 nmol/L) and their complete 
spiking recovery (100%). Laboratory #3 also showed reasonably close agreement with the 
target value for the 5-methylTHF calibrator (23.2 vs. 20 nmol/L), but the laboratory 
displayed high imprecision (median CV 9.8%) and the lowest and most variable spiking 
recovery (mean [SD]: 59% [68%]). This indicates different method performance for serum 
samples and calibrators, possibly because the laboratory did not carry the calibrators through 
the sample extraction process.
We observed larger imprecision for folic acid in serum samples with lower (~1 nmol/L) 
compared to higher folic acid concentration. Laboratories #3 and #4 (both used d4-folic acid 
and did not carry the calibrators through sample extraction) obtained the highest results for 
most serum pools, for SRM 1955 (mean bias: 578% and 236%, respectively), and for the 
folic acid calibrator (6.0 and 6.21 nmol/L, respectively) and showed high imprecision 
(median CV: 20% and 19%, respectively). Other laboratories obtained lower folic acid 
results compared to the CDC laboratory for the serum pools (-63% to -13%; Supplemental 
Table 7) and for the folic acid calibrator (2.32–4.55 vs. 5 nmol/L), and most obtained 
incomplete spiking recoveries (64%–102%). This was unexpected and necessitated a 
thorough investigation.
CDC conducted experiments that compared folic acid primary stock solutions of variable 
concentrations and age, folic acid intermediate stock solutions prepared in water vs. 0.1% 
ascorbic acid, and buffering of the daily calibrator mixture vs. using 0.1% ascorbic acid as 
the diluent. We found problems with folic acid solubility at certain pH and concentration 
conditions (for further details, consult Supplemental Text 1). As a result, the folic acid 
calibrator value was incorrectly assigned (~30% too high) leading to an overestimation of 
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serum concentrations. After correcting the calibration bias, CDC obtained on average 34% 
lower results for the serum pools (Table 3). The new folic acid values for the NIST SRM 
1955 (levels 1, 2, and 3: 0.54, 1.17, and 1.14 nmol/L, respectively) were on average 36% 
lower (Table 8) and in good agreement with the certificate reference values (0.49, 1.05, and 
1.07 nmol/L, respectively). Only 5 laboratories measured lower than the CDC laboratory for 
the serum pools after CDC corrected the calibration bias vs. 12 laboratories before 
(Supplemental Table 7), but the agreement among laboratories was still poor (-43% lower to 
125% higher than the CDC laboratory). The larger imprecision observed for folic acid and 
the large differences in mean relative bias for NIST SRM 1955 (-47% to 578%) among 
laboratories raise the question whether folic acid measurement may be affected by solubility 
issues in other laboratories as well.
Fewer laboratories measured MeFox and most obtained mean results for the 6 serum pools 
within ±15% of the CDC laboratory, except for laboratories #6 (32% lower) and #16 (26% 
higher) (Supplemental Table 7). Laboratory #6 obtained the lowest spiking recovery (66%) 
and the lowest concentration for the MeFox calibrator (3.33 vs. 5 nmol/L), possibly 
indicating a calibration bias. Laboratory #16 showed the highest imprecision (median CV 
30%), but obtained reasonable spiking recovery (90%) and measured close to the target 
value (5.23 vs. 5 nmol/L) for the MeFox calibrator. This may be indicative of sample 
processing issues that lead to large variability.
This study only allowed limited interpretation of results for the 3 minor folate forms because 
concentrations were <LOD in most serum samples and fewer laboratories measured these 
compounds. Nonetheless, some useful information was gained from the spiked serum pool 
and from the calibrators. Laboratory #15 obtained 148% higher 5-formylTHF results in the 
serum pool than the CDC laboratory (Supplemental Table 7), measured higher than the 
target (11.6 vs. 5 nmol/L) for the 5-formylTHF calibrator, and obtained a spiking recovery 
of 259%, indicating a potential calibration bias or interference. Similarly, laboratory #16 
obtained 111% higher 5-formylTHF and 345% higher THF results than the CDC laboratory 
for the serum pool (Supplemental Table 7), measured higher than the target (8.75 vs. 5 
nmol/L for 5-formylTHF; 14.0 vs. 5 nmol/L for THF) for the calibrator, and obtained a 
spiking recovery of 221% for 5-formylTHF and 460% for THF, indicating a potential 
calibration bias or interference for both compounds. Laboratory #4 did not detect any THF 
in the spiked serum pool or in the THF calibrator, and obtained a spiking recovery of 0% for 
THF and 198% for folic acid. This may indicate that THF was lost during sample 
preparation and partially oxidized to folic acid, possibly during the heat extraction. 
Laboratory #3 showed the highest imprecision for 5-formylTHF (22%) and THF (38%), 
which could again be related to sample processing.
The results of the random effects models confirmed many of the observations made from 
figures and descriptive statistics. However, some aspects such as the independent and 
unbiased estimation of the 3 sources of variability can only be elucidated by a statistical 
model. The model results showed that for most laboratories the between-day variance was 
smaller than the within-day variance. Specifically, for 5-methylTHF, the model estimated a 
zero between-day GCV for half of the laboratories. While intuitively unappealing, as one 
expects observations within days to be more correlated than between days, this type of 
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observation can be a characteristic of data. We confirmed that the average percent change in 
the absolute difference of the geometric means between day 1 and day 2 was smaller for 
laboratories with an estimated zero between-day GCV (1.0%, 1.1%, and 1.6% for 5-
methylTHF, MeFox, and folic acid, respectively) compared to the remaining laboratories 
(7.3%, 7.3%, and 18.0%, respectively). Laboratory #6 had the largest between-day variance 
for 5-methylTHF (10.9%), which seemed to have been caused by variability in the 
calibration curve parameters. The models further confirmed that group 1 and group 2 
laboratories seemed to achieve similar results in imprecision across the analytes and also 
identified more issues with the reproducibility for folic acid compared to 5-methylTHF and 
MeFox, as noted by the larger between-sample GCV and rc.
In summary, these Round Robin studies for the measurement of serum folate forms by 
HPLC-MS/MS demonstrated the great value of conducting a systematic sample exchange 
with peer laboratories. Studies like this are an effective way to assess questions of laboratory 
comparability and method performance. It would be desirable if an external quality 
assessment scheme for the measurement of serum folate forms could be developed or if 
these analytes could be added to existing proficiency testing challenges that assess 
performance of total folate. Reference materials with certified concentrations for folate 
forms in addition to 5-methylTHF and for total folate are urgently needed to improve 
method accuracy. It was reassuring that the agreement among laboratories was better when 
the same method was used in different laboratories (group 2), but also that independently-
developed methods can achieve similar results (group 1). This study also showed that errors 
in method calibration are a common source for inaccurate results. The reproducibility of a 
procedure in multiple laboratories and the comparability of different procedures are key 
requirements in the successful harmonization of biomarker measurements. This study is a 
first step towards that goal.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Box-and-whisker plots of individually measured concentrations in 6 serum pools by group-
laboratory for 5-methylTHF (panel A), folic acid (panel B), and MeFox (panel C). G0-L10 
is the CDC laboratory; G1-L1 to G1-L7 are group 1 laboratories (used independently-
developed HPLC-MS/MS methods); G2-L11 to G2-L16 are group 2 laboratories (used an 
adapted CDC method). Not all laboratories measured MeFox. The line and box represent the 
median and the 1st to 3rd quartiles, respectively; the whiskers are extending 1.5 * IQR from 
each quartile; observed values greater than 1.5 * IQR from each quartile are highlighted as 
possible near outliers. Each pool was measured in duplicate over 2 days, n = 4. 5-
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MethylTHF, 5-methyltetrahydrofolate; MeFox, pyrazino-s-triazine derivative of 4α-
hydroxy-5-methylTHF.
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Figure 2. 
Box-and-whisker plots of imprecision (CV) for 6 serum pools by group-laboratory for 5-
methylTHF (panel A), folic acid (panel B), and MeFox (panel C). G0-L10 is the CDC 
laboratory; G1-L1 to G1-L7 are group 1 laboratories (used independently-developed HPLC-
MS/MS methods); G2-L11 to G2-L16 are group 2 laboratories (used an adapted CDC 
method). Not all laboratories measured MeFox. The line and box represent the median and 
the 1st to 3rd quartiles, respectively; the whiskers are extending 1.5 * IQR from each 
quartile; observed values greater than 1.5 * IQR from each quartile are highlighted as 
possible near (+) or far (⁎) outliers. Each pool was measured in duplicate over 2 days, n = 4. 
Fazili et al. Page 15
J Nutr. Author manuscript; available in PMC 2018 September 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
5-MethylTHF, 5-methyltetrahydrofolate; MeFox, pyrazino-s-triazine derivative of 4α-
hydroxy-5-methylTHF.
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Figure 3. 
Mean concentrations measured in CDC folate calibrators for 5-methylTHF (panel A), folic 
acid (panel B), 5-formylTHF (panel C), THF (panel D), 5,10-methenylTHF (panel E), and 
MeFox (panel F). Black bars represent single calibrators; grey bars represent mixed 
calibrators; error bars represent SD. Laboratory #10 is the CDC laboratory; laboratories #1–
#7 (group 1) used independently-developed HPLC-MS/MS methods; laboratories #11–#16 
(group 2) used an adapted CDC method. Not all laboratories measured 5-formylTHF, THF, 
5,10-methenylTHF, and MeFox. Each calibrator was measured in duplicate over 2 days, n = 
4. 5-Methyltetrahydrofolate, 5-methylTHF, 5-formylTHF, 5-formyltetrahydrofolate; THF, 
tetrahydrofolate; 5,10-methenylTHF, 5,10-methenyltetrahydrofolate; and MeFox, pyrazino-
s-triazine derivative of 4α-hydroxy-5-methylTHF.
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